ANK-203 / Ankyra Therap - LARVOL DELTA

Ankyra Therapeutics Presents First Preclinical Data on ANK-203, a Novel CD137-Anchored Immunotherapy Candidate, in Oral Session at AACR IO (Businesswire) - "In preclinical studies, ANK-203 demonstrated robust activation of the CD137 (4-1BB) immune pathway and regression of established tumors following localized administration. Treatment was well tolerated, with no significant safety signals observed. In addition to local tumor control, ANK-203 induced anti-tumor responses in distant, untreated tumors, suggesting the induction of a systemic immune response."

Preclinical • Oncology